Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
2,073 articles
📰
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key...
Prologis and GIC Form $1.6 billion U.S. Build-to-Suit Logistics Joint Venture
Partnership to Fund Build-to-Suit Distribution Projects Across Major U.S. Markets SAN FRANCISCO and SINGAPORE, March 19, 2026 /PRNewswire/ --...
📰
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key...
📰
Primary Care Physician Use of Counterpart Assistant Associated with 18%–22% Fewer Flu-Related Acute Care Events Among COPD and CHF Patients
Primary Care Physician Use of Counterpart Assistant Associated with 18%–22% Fewer Flu-Related Acute Care Events Among COPD and CHF Patients
110,064 Shares in Eli Lilly and Company $LLY Bought by CIBC Bancorp USA Inc.
CIBC Bancorp USA Inc. purchased a new stake in Eli Lilly and Company (NYSE:LLY – Free Report) during the 3rd quarter, according to the company...
110,064 Shares in Eli Lilly and Company $LLY Bought by CIBC Bancorp USA Inc.
CIBC Bancorp USA Inc. purchased a new stake in Eli Lilly and Company (NYSE:LLY – Free Report) during the 3rd quarter, according to the company...
110,064 Shares in Eli Lilly and Company $LLY Bought by CIBC Bancorp USA Inc.
CIBC Bancorp USA Inc. purchased a new stake in Eli Lilly and Company (NYSE:LLY – Free Report) during the 3rd quarter, according to the company...
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for...
📰
Aveanna Healthcare (AVAH) Beats Q4 Earnings and Revenue Estimates
Aveanna (AVAH) delivered earnings and revenue surprises of +38.78% and +5.64%, respectively, for the quarter ended December 2025. Do the numbers hold...
📰
Aveanna Healthcare (AVAH) Beats Q4 Earnings and Revenue Estimates
Aveanna (AVAH) delivered earnings and revenue surprises of +38.78% and +5.64%, respectively, for the quarter ended December 2025. Do the numbers hold...
CORVEX ANNOUNCES CLOSING OF ALL-STOCK MERGER
Upon the 2026 Stockholders' Meeting to be held in May 2026, subject to approval by the stockholders and board of directors of the Company, Corvex...
📰
CORVEX ANNOUNCES CLOSING OF ALL-STOCK MERGER
Upon the 2026 Stockholders' Meeting to be held in May 2026, subject to approval by the stockholders and board of directors of the Company, Corvex...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers
Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers
Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers
Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers
Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers
Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers
Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers
Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers
Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers
Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers
Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers
Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market...
Aerolínea brasileña GOL lanza venta de pasajes para vuelos intercontinentales directos entre Brasil y Portugal"
SÃO PAULO, 19 de marzo de 2026 /PRNewswire/ -- La aerolínea brasileña GOL Linhas Aéreas, que ahora inicia su fase intercontinental tras el reciente...
📰
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage,...
📰
Picard Medical / SynCardia Highlight Second Successful Total Artificial Heart Bridge to Transplant at UCSF Health
Case highlights young patient supported for 119 days with the SynCardia Total Artificial Heart before successful heart transplantation Case...
📰
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer’s...
📰
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete...
📰
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio –
– Enables...
📰
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis Three-year collaboration...
📰
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance along with preparations to launch the PSC Phase 3...
📰
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis...
📰
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio –
📰
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus...
📰
Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
📰
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
JENA, Germany, March 19, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory...
📰
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives...
📰
BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health
BURLINGTON, Mass. and JERUSALEM, March 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a...
📰
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and...
📰
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer’s disease (AD)...
📰
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2026...